Cancer Diagnostics Global Market Report 2023

Description

“Cancer Diagnostics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cancer diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Products: Companion Diagnostics; Molecular Diagnostics

2) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users

3) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging

4) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications

Companies Mentioned: Abbott; Becton Dickinson and Company; Hoffmann-La Roche Ltd.; GE Healthcare Ltd.; Thermo Fisher Scientific

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the cancer diagnostics market are: Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc.

The global cancer diagnostics market will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The cancer diagnostics market is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%.

The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients.

North America was the largest region in the cancer diagnostics market in 2022. Asia Pacific was the second-largest region in the cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others.

A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030.

Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older.

The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%.

The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices.

The countries covered in the cancer diagnostics market are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r1871

1. Executive Summary

2. Cancer Diagnostics Market Characteristics

3. Cancer Diagnostics Market Trends And Strategies

4. Cancer Diagnostics Market - Macro Economic Scenario

4.1 COVID-19 Impact On Cancer Diagnostics Market

4.2 Ukraine-Russia War Impact On Cancer Diagnostics Market

4.3 Impact Of High Inflation On Cancer Diagnostics Market

5. Cancer Diagnostics Market Size And Growth

5.1. Global Cancer Diagnostics Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global Cancer Diagnostics Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. Cancer Diagnostics Market Segmentation

6.1. Global Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Companion diagnostics
Molecular diagnostics
6.2. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Cancer Research Institutes
Diagnostic Laboratories
Hospitals
Other End Users
6.3. Global Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Biopsy
Endoscopy
Tumor Biomarker Tests
Imaging
6.4. Global Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Cervical Cancer
Breast Cancer
Liver Cancer
Blood Cancer
Kidney Cancer
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Melanoma
Other Applications

7. Cancer Diagnostics Market Regional And Country Analysis

7.1. Global Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Cancer Diagnostics Market

8.1. Asia-Pacific Cancer Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.4. Asia-Pacific Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Cancer Diagnostics Market

9.1. China Cancer Diagnostics Market Overview
9.2. China Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.4. China Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Cancer Diagnostics Market

10.1. India Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.3. India Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Cancer Diagnostics Market

11.1. Japan Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.3. Japan Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Cancer Diagnostics Market

12.1. Australia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.3. Australia Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Cancer Diagnostics Market

13.1. Indonesia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.3. Indonesia Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Cancer Diagnostics Market

14.1. South Korea Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.3. South Korea Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Cancer Diagnostics Market

15.1. Western Europe Cancer Diagnostics Market Overview
15.2. Western Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.4. Western Europe Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Cancer Diagnostics Market

16.1. UK Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.3. UK Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Cancer Diagnostics Market

17.1. Germany Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.3. Germany Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Cancer Diagnostics Market

18.1. France Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.3. France Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Cancer Diagnostics Market

19.1. Eastern Europe Cancer Diagnostics Market Overview
19.2. Eastern Europe Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.4. Eastern Europe Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Cancer Diagnostics Market

20.1. Russia Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.3. Russia Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Cancer Diagnostics Market

21.1. North America Cancer Diagnostics Market Overview
21.2. North America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.4. North America Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Cancer Diagnostics Market

22.1. USA Cancer Diagnostics Market Overview
22.2. USA Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.4. USA Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Cancer Diagnostics Market

23.1. South America Cancer Diagnostics Market Overview
23.2. South America Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.4. South America Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Cancer Diagnostics Market

24.1. Brazil Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.3. Brazil Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Cancer Diagnostics Market

25.1. Middle East Cancer Diagnostics Market Overview
25.2. Middle East Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.4. Middle East Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Cancer Diagnostics Market

26.1. Africa Cancer Diagnostics Market Overview
26.2. Africa Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.4. Africa Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Cancer Diagnostics Market Competitive Landscape And Company Profiles

27.1. Cancer Diagnostics Market Competitive Landscape
27.2. Cancer Diagnostics Market Company Profiles
- 27.2.1. Abbott
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. Becton Dickinson and Company
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Hoffmann-La Roche Ltd
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. GE Healthcare Ltd.
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. Thermo Fisher Scientific
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Cancer Diagnostics Market

29. Cancer Diagnostics Market Future Outlook and Potential Analysis

30. Appendix

30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. The Business Research Company
30.6. Copyright And Disclaimer